“o. itemList. length” “this. config. text. ariaShown”
“This. config. text. ariaFermé”
By Umar Farooq
ISLAMABAD (Reuters) – The drop in the number of COVID-19 infections in Pakistan will not be a phase 3 clinical trial for a prospective vaccine in progression through China CanSino Biologics, which is expected to begin this month, according to test culprits.
Last month, Pakistan’s drug regulator approved the country’s first Phase 3 clinical trial for CanSino’s candidate, Ad5-nCoV, to be conducted through the government-controlled National Institute of Health (NIH) with pharmaceutical company AJM: CanSino’s representative.
“We plan to release the allocation on September 20, or in the month,” Hassan Abbas Zaheer, who heads the AJM trial, told Reuters.
The Ad5-nCoV vaccine and placebo injections will be won in Pakistan next week.
Daily positive cases in Pakistan peaked at more than 6,000 in June, but have fallen dramatically since then, with 426 new cases detected on 8 September, bringing the total to 299,659 and 6,359 deaths.
Zaheer said the low positive rates do not imply that COVID-19 is no longer being provided in the country and that the possibility of infection of those vaccinated as a component of the trial is sufficient to prove their immunity.
“We think other people are still inflamed but haven’t been tested, so the virus is still there,” he said.
Pakistan, a country of more than 220 million inhabitants, between 20,000 and 30,000 a day.
NIH Executive Director Aamer Ikram told Reuters officials that the prevalence of the virus in Pakistan is low, despite the low testing rate, but researchers have a test-ready plan.
“We have developed a strategy with CanSino on how to recruit as volunteers who are most threatened by the virus, so we will focus on frontline staff who are most likely to be exposed.
The Ad5-nCoV trial will recruit approximately 8,000 volunteers, the maximum of whom will be fitness workers. They will be recruited over a four-month era and tracked for 12 months after receiving the vaccine or placebo.
(Report through Umar Farooq; Editing via Elaine Hardcastle)